Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


Daily capsule for patients with skin cancer

Patients with a rare form of skin cancer could now benefit from first-of-a-kind once daily capsule


Erivedge® (vismodegib), a new medicine that has been shown to help patients with a disfiguring and potentially life-threatening form of skin cancer, is now registered for use in New Zealand.

Erivedge is a first-in-class Hedgehog Pathway Inhibitor that helps shrink disfiguring or potentially life-threatening lesions in advanced skin cancer

AUCKLAND – 23 April 2014: From today, adult New Zealanders with metastatic basal cell carcinoma (mBCC) or locally advanced BCC (laBCC) where treatment with surgery or radiotherapy is inappropriate, could benefit from Erivedge®. 1 This makes Erivedge, a capsule taken once daily, the only registered medicine for advanced BCC (aBCC, is comprised of mBCC and laBCC) fulfilling an unmet medical need in this group of patients.1

BCC is the most common type of skin cancer in the world. 2 It is estimated that in 2006 there were 43,900 New Zealanders diagnosed with BCC and that this number is growing year on year.

BCC forms the majority (65% - 75%) of non-melanoma skin cancers (NMSC). In 2006, NMSC was estimated to have incurred NZ$51.4 million in healthcare costs (excluding GST) and NZ$6.7 million in lost production.

BCC is considered curable when confined to the skin.

However, in some cases the disease will invade surrounding tissue (locally advanced) or spread to other parts of the body (metastatic BCC) in a manner that cannot be effectively treated with surgery or radiation.
Dr Richard Martin, Cutaneous Surgical Oncologist, says that advanced basal cell carcinoma can be highly disfiguring and can significantly impact quality of life.

“Until now, there have not been any active treatment options available for patients who are not appropriate for surgery or radiotherapy. Erivedge, which has been shown to shrink tumours, addresses this unmet need and is a welcome new treatment option for patients with advanced BCC,” said Dr Martin.

An independent review facility assessment found that Erivedge shrank visible lesions in 43 percent (27/63) of patients with locally advanced BCC inappropriate for surgery or radiotherapy and shrank tumours in 30 percent (10/33) of those with metastatic BCC.

An application for funding will be submitted to PHARMAC in due course. In the interim, Erivedge will be available for private purchase .

-ENDS-

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

BusinessDesk: APN's NZME Sees Future In Paywalls, Growth In Digital Sales

APN News & Media has touted a single newsroom concept for its NZME unit in New Zealand, similar to what Germany's Die Welt uses, saying an 'integrated sales proposition' is helping it win market share, including ... More>>

Labour Party: Global Milk Prices Now Lowest In 6 Years

The latest fall in the global dairy price has brought it to the lowest level in six years and shows there must be meaningful action in tomorrow’s Budget to diversify the economy, says Labour’s Finance spokesperson Grant Robertson. “Dairy prices ... More>>

BusinessDesk: NZ Inflation Expectations Creep Higher In June Survey

May 19 (BusinessDesk) - New Zealand businesses lifted their expectations for inflation over the next two years, sapping any immediate pressure on the Reserve Bank to cut interest rates, and prompting the kiwi dollar to jump higher. More>>

BusinessDesk: Lower Fuel Costs Drive Down NZ Producer Input, Output Prices

May 19 - Producer input and output prices fell in the first quarter, mainly reflecting lower fuel costs and weakness in prices of meat and dairy products. More>>

Media: Fairfax Media NZ Announces Senior Editorial Team

Fairfax Media New Zealand has today confirmed its new editorial leadership team, as part of a transformation of its newsrooms aimed at enhancing local and national journalism across digital and print. More>>

Science: Flavonoids Reduce Cold And Cough Risk

Flavonoids reduce cold and cough risk Research from the University of Auckland shows eating flavonoids – found in green tea, apples, blueberries, cocoa, red wine and onions – can significantly reduce the risk of catching colds and coughs. The research, ... More>>


BusinessDesk: RBNZ House Alert Speech The Catalyst For Government Action

Prime Minister John Key all but conceded that pressure from the Reserve Bank of New Zealand for concerted action on rampant Auckland house prices was one of the main catalysts for the government's weekend announcements about tightly ... More>>

BusinessDesk: How To Fall Foul Of The New Housing Tax Rules: Tips From IRD

Just because you rented out your investment property doesn't absolve you from paying tax, says the Inland Revenue Department in a summary of commonly made mistakes by non-professional property investors when it comes to their tax liability.More>>

Legal: Superdiversity Law, Policy And Business Stocktake Announced

Mai Chen, Managing Partner at Chen Palmer New Zealand Public and Employment Law Specialists and Adjunct Professor of Law at the University of Auckland, today announced the establishment ... More>>

Housing: More House Price Gains Expected

House price expectations remain high, with a net 56% of respondents expecting house prices will increase. Fears of higher interest rates are fading, consistent with the RBNZ’s signals this year. Affordability and a lack of houses for ... More>>

TDDA: State-Of-The-Art Drug Testing Laboratory To Open In Auckland

World leading drug testing agencies, The Drug Detection Agency (TDDA) and Omega Laboratories, open New Zealand laboratory More>>

Network: Bigpipe Launches Ultra-Fast Broadband Into Wellington

Bigpipe Launches Ultra-Fast Broadband into Wellington Naked broadband provider Bigpipe has extended its national reach, announcing today, the launch of its unlimited UFB offering into Wellington. The Spark Venture business is giving Wellingtonians the ... More>>

Get More From Scoop

 
 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news